Physician profile

Ammar Hasnie

Lexington, KY

NPI 1699396051

$6,297.78

in general payments reported to CMS, 2019-2025

4 companies · $5,409 in 2025

The $5,409 reported for 2025 was more than what 98% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$4,521.86
Food and Beverage$1,725.92
Education$50.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $3,733.13 2023-2025 Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan
Abbott Laboratories $2,486.18 2025 Merlin@Home, Cardiomems, Mitraclip
Abiomed $56.39 2025
Kiniksa Pharmaceuticals International, Plc $22.08 2024 Arcalyst

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ammar Hasnie

$6,297.78

in general payments reported 2019-2025

Years
2023-2025
Top company
Medtronic, INC.
Context
The $5,409 reported for 2025 was more than what 98% of providers received nationally.

https://glasscript.com/doctor/11557696/ammar-hasnie

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.